(UH) peptide UH-RA.1, which have predictive value for an early response to therapy. Antibody reactivity to UH-RA.1 was found in 7%–10% of early RA patients. Presence of anti-UH-RA.1 antibodies in baseline samples from the Leiden Early Arthritis Clinic (EAC) cohort (n=600) appeared to be related to a better outcome as 37% of the antibody-positive group vs 21% of the antibody-negative group reached sustained DMARD-free remission ($p=0.016$)¹.

Objectives: Our aim is to test the relation between antibody reactivity against UH-RA.1 peptide and early disease remission in baseline RA samples from the CareRA cohort.

Methods: Using a custom peptide enzyme-linked immunosorbent assay, the presence of anti-UH-RA.1 antibodies was investigated in the well characterised CareRA cohort². Cut-off for seropositivity was defined by $2 \times$ SD above the mean antibody level of the healthy control group¹. In the CareRA trial, different treatment regimens consisting of synthetic DMARDs combined with a step down glucocorticoid treatment, were studied. We used 223 baseline RA samples, collected before the start of treatment and early disease remission was defined as a DAS28 (CRP) <2.6 at week 16.

Results: Antibodies to UH-RA.1 were found in 5% of the baseline samples from the CareRA cohort. Presence of anti-UH-RA.1 antibodies did not seem to be related to early disease remission in the CareRA cohort. Of the antibody positive group, 9/11 (82%) were in remission at week 16, while 152/212 (72%) of the antibody negative group reached early disease remission ($p=0.37$). However, in UH-RA.1 seropositive patients from the CareRA cohort, antibody levels were found to be significantly higher in baseline samples of patients that reached remission in week 16 (mean rank 120.51 vs 89.9, $p=0.001$).

Conclusions: In RA patients, presence of antibodies against UH-RA.1 peptide at baseline is related to sustained DMARD-free remission and high levels of antibodies against UH-RA.1 were correlated with early remission after combination therapy consisting of classical synthetic DMARDs with a step down glucocorticoid treatment. In combination with other predictive markers, antibodies against UH-RA.1 peptide might therefore contribute to an improved early patient stratification and prediction of therapy response.

REFERENCES:

- [1] De Winter, et al. *Rheumatology* (Oxford) 2016;55(8):1431–6.
- [2] Verschuere P, et al. *Ann Rheum Dis* 2015;74:27–34.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.6470

AB0293 FREQUENCY OF JOINT EROSIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH BIOLOGICS IN RELATION TO RF AND ACPA SEROLOGY IN REAL LIFE

L. Heeman¹, F. Van den Bosch^{1,2}, D. Elewaut^{1,2}, P. Carron^{1,2}, P. Jacques^{1,2}.

¹Rheumatology, University Hospital; ²Inflammation Research Center, VIB, Ghent, Belgium

Background: Rheumatoid arthritis (RA) is a chronic auto-immune disease, characterised by a symmetric polysynovitis and extra-articular manifestations. In 70% to 80% of patients with RA, serologic factors like Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) are present. Early recognition and treatment with disease-modifying antirheumatic drugs (DMARDs) is important in achieving control of disease and prevention of joint destruction. If it is untreated or unresponsive to therapy, inflammation destroys cartilage and bone, resulting in irreversible bone erosions. The 2016 EULAR recommendations for the management of RA stipulate that MTX is recommended as first-line strategy plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails, stratification is recommended. Without unfavourable prognostic markers, switching to, or adding another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD or Jak-inhibitor should be added to the csDMARD.

Objectives: To determine an association between serology status and prevalence of radiographic erosions, the use of biologics and prevalence of erosions, and serology status and use of biologics.

Methods: Data were obtained from the electronic patient files of patients who visited the department of Rheumatology at the University Hospital of Ghent (Belgium) between October and December 2016. Patient characteristics with respect to diagnosis, treatment, serology status and erosion status were collected. The

data has been statistically analysed using χ^2 -, Fisher's exact, Kolmogorov-Smirnov or Kruskal-Wallis tests with $\alpha=0.05$.

Results: A total of 2001 consultations were analysed, of which 358 patients were identified with RA. 353 patients were included, of which 116 men (32.9%) and 237 women (67.1%). The mean age of the study population was 62 years with a mean age of 52 years at diagnosis. Of these patients, 36.0%, 49.5% and 29.8% were positive for respectively RF, ACPA and RF +ACPA. 38% has ever been treated with a biologic, whereas 26.9% is currently treated with a biologic. 37.4% of the patients showed erosions on a recent radiograph of hands or feet. A positive ACPA serology ($p<0.0001$, OR=1.87), a positive RF serology ($p=0.010$, OR=2.26) and a positive RF +ACPA serology ($p=0.007$, OR=2.74) was more observed in patients with radiographic erosions. A significant difference in erosions was seen between patients treated with or without biologics ($p<0.0001$, OR=3.45). Biologics were prescribed more in patients with positive ACPA serology ($p<0.0001$, OR=3.92) and in patients with positive RF serology ($p=0.001$, OR=2.67).

Conclusions: In a consecutive real life cohort of patients with RA, positive ACPA and/or RF status were associated with an increased risk to develop bone erosions in affected joints. Positive serology was also linked to biologic therapies. Patients who received biological treatment were more prone to have erosions.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4709

AB0294 TREATMENT MODES IN RHEUMATOID ARTHRITIS: FACTORS INFLUENCING PATIENT PREFERENCE

P.C. Taylor¹, N. Betteridge², T.M. Brown³, J. Woolcott⁴, A.J. Kivitz⁵, C. Zerbini⁶, D. Whalley⁷, O. Oluyinka-Amayo⁸, C. Chen⁹, P. Dahl⁹, D. Ponce de Leon¹⁰, D. Gruben¹¹, L. Fallon¹². ¹Botnar Research Centre, University of Oxford, Oxford; ²Neil Betteridge Associates, London, UK; ³RTI Health Solutions, Research Triangle Park, NC; ⁴Pfizer Inc, Collegeville, PA; ⁵Altoona Center for Clinical Research, Duncansville, PA, USA; ⁶Centro Paulista de Investigação Clínica, São Paulo, Brazil; ⁷RTI Health Solutions, Manchester, UK; ⁸Pfizer Inc, New York, NY, USA; ⁹Pfizer Inc, Ballerup, Denmark; ¹⁰Pfizer Inc, Lima, Peru; ¹¹Pfizer Inc, Groton, CT, USA; ¹²Pfizer Canada, Montreal, QC, Canada

Background: Little in-depth qualitative research has been conducted to investigate reasons for rheumatoid arthritis (RA) patient (pt) preferences for different modes of treatment administration. An understanding of pt preference can help physicians personalise therapy recommendations.

Objectives: To describe potential RA pt preferences for RA treatment modes and reasons for these preferences.

Methods: Pt demographic information was obtained at screening alongside qualitative interviews conducted using a semi-structured interview guide among adult RA pts in the US, UK, France, Germany, Italy, Spain, Switzerland and Brazil who were currently taking a DMARD (biologic or non-biologic). A 100-point allocation task was used to evaluate the strength of preference (0–100; 100=strong) across 4 treatment modes: oral (OR; once daily), self-injection (SI; weekly), clinic-injection (CI; weekly) and infusion (INF; monthly). Transcripts were developed in English; ATLAS.ti software (v7.5) was used for qualitative coding and analysis.

Results: 100 interviews (30 US; 10 in each of 7 other countries) were conducted (female: 75.0%; mean age: 53.9 years; mean time since diagnosis: 11.6 years). Current RA medication mode included OR (60.0%), injection (57.0%) and INF (14.0%); 79.0% and 37.0% of pts had experience with injection and INF medications, respectively; 31.0% of pts were taking a combination of biologic and non-biologic DMARDs. Among the 4 treatment modes, OR was allocated the highest mean (standard deviation [SD]) preference points (47.3 [33.1]) and the greatest percentage of pts with a 1st choice rank (57.0%); this was followed by SI (29.7 [27.7]; 29.0%), INF (15.4 [24.6]; 16.0%) and CI (7.5 [14.1]; 2.0%). Preferences by country suggested that the mean points allocated to OR were greater in the US vs other countries. Across all pts and treatment modes, 56.0% of pts had a 'strong' 1st choice preference (ie, a pt allocation $\geq$ the mean pts across the 1st ranked choices [70]); of these pts, the majority chose OR (62.5%); SI: 23.2%; INF: 10.7%; CI: 3.6%). Speed of administration was among the most common reasons for choosing OR or SI as a 1st choice, together with ease of administration (OR) and frequency of dosing (SI; table 1). Difficulty remembering was the most common reason for not choosing OR and avoidance of pain was the most common reason for not choosing SI as a 1st choice.

Conclusions: More pts preferred OR as an RA treatment mode, followed by SI. Rationales for preference included ease of use, concerns about drug interactions, dosing frequency, feelings of control and avoidance of pain and needles. While 56.0% of pts felt strongly about their 1st choice preference, nearly half did not and may be receptive to and benefit from discussions with their healthcare professional and/or pt support groups about RA treatment mode options.